AbbVie Operating Income 2010-2019 | ABBV

AbbVie annual/quarterly operating income history and growth rate from 2010 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • AbbVie operating income for the quarter ending September 30, 2019 was $2.617B, a 17.16% decline year-over-year.
  • AbbVie operating income for the twelve months ending September 30, 2019 was $6.586B, a 37.9% decline year-over-year.
  • AbbVie annual operating income for 2018 was $6.383B, a 33.13% decline from 2017.
  • AbbVie annual operating income for 2017 was $9.545B, a 2.19% increase from 2016.
  • AbbVie annual operating income for 2016 was $9.34B, a 23.92% increase from 2015.
AbbVie Annual Operating Income
(Millions of US $)
2018 $6,383
2017 $9,545
2016 $9,340
2015 $7,537
2014 $3,411
2013 $5,664
2012 $5,817
2011 $3,620
2010 $4,717
2009 $4,932
AbbVie Quarterly Operating Income
(Millions of US $)
Q3 2019 $2,617
Q2 2019 $3,400
Q1 2019 $3,010
Q4 2018 $-2,441
Q3 2018 $3,159
Q2 2018 $2,762
Q1 2018 $2,903
Q4 2017 $1,782
Q3 2017 $2,694
Q2 2017 $2,662
Q1 2017 $2,407
Q4 2016 $2,314
Q3 2016 $2,361
Q2 2016 $2,387
Q1 2016 $2,278
Q4 2015 $2,113
Q3 2015 $1,885
Q2 2015 $1,852
Q1 2015 $1,687
Q4 2014 $-415
Q3 2014 $960
Q2 2014 $1,515
Q1 2014 $1,351
Q4 2013 $1,535
Q3 2013 $1,371
Q2 2013 $1,453
Q1 2013 $1,305
Q4 2012 $1,821
Q3 2012 $1,596
Q2 2012 $1,422
Q1 2012 $978
Q4 2011 $-5,887
Q3 2011 $4,409
Q2 2011 $4,274
Q1 2011 $824
Q4 2010
Q4 2009
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $127.948B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $359.093B 15.56
Roche Holding AG (RHHBY) Switzerland $261.818B 0.00
Merck (MRK) United States $217.580B 16.86
Pfizer (PFE) United States $208.858B 12.41
Novartis AG (NVS) Switzerland $207.477B 17.51
Novo Nordisk (NVO) Denmark $127.967B 22.06
AstraZeneca (AZN) United Kingdom $124.917B 22.56
Sanofi (SNY) France $118.120B 14.51
Eli Lilly (LLY) United States $110.175B 20.35
GlaxoSmithKline (GSK) United Kingdom $109.820B 13.30
Bristol-Myers Squibb (BMY) United States $92.625B 12.95
Bayer (BAYRY) Germany $70.650B 10.46
H Lundbeck (HLUYY) Denmark $7.388B 10.66